Soros Capital Management LLC Invests $5.79 Million in Danaher Co. (NYSE:DHR)

Soros Capital Management LLC acquired a new position in Danaher Co. (NYSE:DHR) during the third quarter, according to its most recent filing with the SEC. The firm acquired 20,837 shares of the conglomerate’s stock, valued at approximately $5,793,000. Danaher comprises approximately 1.4% of Soros Capital Management LLC’s holdings, making the stock its 24th biggest holding.

A number of other large investors have also recently made changes to their positions in DHR. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher in the 2nd quarter worth approximately $25,000. nVerses Capital LLC bought a new stake in shares of Danaher in the 2nd quarter worth approximately $25,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the 3rd quarter worth approximately $40,000. MFA Wealth Advisors LLC bought a new stake in shares of Danaher in the 2nd quarter worth approximately $51,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Danaher in the 2nd quarter worth approximately $51,000. 79.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. UBS Group dropped their price target on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Robert W. Baird dropped their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Evercore ISI boosted their price target on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus boosted their price target on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Finally, TD Cowen boosted their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $287.16.

Danaher Trading Down 0.5 %

NYSE:DHR opened at $236.53 on Wednesday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. The firm has a market capitalization of $170.84 billion, a price-to-earnings ratio of 45.14, a price-to-earnings-growth ratio of 4.37 and a beta of 0.85. Danaher Co. has a one year low of $215.68 and a one year high of $281.70. The business has a fifty day moving average price of $256.66 and a 200-day moving average price of $259.81.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the business posted $2.02 EPS. Danaher’s revenue for the quarter was up 3.1% compared to the same quarter last year. Sell-side analysts forecast that Danaher Co. will post 7.5 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. Danaher’s dividend payout ratio is 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.